Mark Agulnik, MD

Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California, United States

Presentation(s):

• Paper 58 - A PHASE IA/IB STUDY OF BOTENSILIMAB, A NOVEL INNATE/ADAPTIVE IMMUNE ACTIVATOR, PLUS BALSTILIMAB FOR THE TREATMENT OF PATIENTS WITH SARCOMA

  Friday, November 18, 2022
  4:15 PM – 4:23 PM